Diltiazem and Exercise Performance in Patients with Chronic Atrial Fibrillation

Atwood, J. Edwin; Myers, Jonathan; Sullivan, Michael J.; Forbes, Susan; Pewen, William; Froelicher, Victor F.

doi:10.1378/chest.93.1.20

Cited by 51 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infusions of diltiazem may be used for more prolonged control of heart rate [96], although intravenous diltiazem is not available in the UK. Oral diltiazem may be used to control heart rate in chronic atrial fibrillation without reducing exercise capacity [97]. The combination of diltiazem and digoxin may result in improved control of heart rate at rest and during exercise compared with either drug given alone [98].…”

Section: Class IV Agents -Calcium Channel Blockersmentioning

confidence: 99%

The peri‐operative management of atrial fibrillation

Nathanson

Gajraj

1998

Anaesthesia

View full text Add to dashboard Cite

SummaryAtrial fibrillation is a common arrhythmia frequently seen in surgical patients. The onset of new atrial fibrillation during the peri-operative period is less common. There are many possible precipitating factors, although volatile agents themselves may have an antifibrillatory action. The management of atrial fibrillation includes removal of any precipitating factors and treatment of the arrhythmia itself. Immediate management of acute-onset atrial fibrillation is usually direct current cardioversion. Alternatively, anti-arrhythmic drugs can be used to achieve cardioversion. In patients with rapid, chronic atrial fibrillation or those refractory to cardioversion, priority is given to control of the ventricular rate. Thrombo-embolism is a significant risk if atrial fibrillation is paroxysmal or persists for more than 48 h.

show abstract

Section: Class IV Agents -Calcium Channel Blockersmentioning

confidence: 99%

The peri‐operative management of atrial fibrillation

Nathanson

Gajraj

1998

Anaesthesia

View full text Add to dashboard Cite

show abstract

“…These results suggest that S-2150 is a favorable hypotensive agent for hypertensive patients with ischemic heart disease [312]. Diltiazem / once 120 mg or 3x80 mg daily per os lowered VR in patients with AF [296] Diltiazem / 4x60 mg per os reduced the maximal and submaximal HRs during exercise [297] Diltiazem / bolus of either 150 or 300 µg/kg over 2 minutes intravenously converted VT to SR, reduced HR to 100 beats/min [302] Diltiazem / continuous infusion of for 24 h (minimum dose, 0.l reduced the incidence of AF after coronary bypass grafting [305] mg/kg/h) Diltiazem / 0.2 mg/kg intravenously for 3 minutes terminated programmed electrical stimulation induced SVT at high right atrium [310] Clentiazem (TA-3090) / 0.1 mg/kg intravenously for 3 minutes terminated programmed electrical stimulation induced SVT at high right atrium [310] Clentiazem / 80 and 120 mg/day antianginal action in patients with stable angina [311] Clentiazem / 80 and 120 mg/day induced first-degree AV block as a sideeffect in patients with stable angina [311] 9.3. Other CCAs Semotiadil (SD-3211) Animal studies with semotiadil…”

Section: S-2150mentioning

confidence: 97%

“…Moreover, in a study involving 180 patients with rapid AF, low-dose diltiazem (≤ 0.2 mg/kg as a starting intravenous bolus) proved to be as effective as the standard dose of 0.25 mg/kg (according to the 2006 guidelines developed by the American College of Cardiology/American Heart Association/European Society of Cardiology for the management of patients with AF) in adequate rate control but the complication of hypotension was seen significantly less frequently 18 vs. 35 % in low and standard doses, respectively [295]. Oral diltiazem treatment also effectively lowered VR in patients with AF [296] and also reduced the maximal and submaximal HRs during exercise without affecting oxygen uptake, minute ventilation, respiratory exchange ratio or BP [297]. The effects of diltiazem on exercise tolerance are controversial in chronic AF as one study found a modest improvement similarly to that observed with verapamil [229] while another found no benefit in terms of improving either exercise tolerance or CO with either diltiazem or verapamil [228].…”

Section: Anipamil Animal Studies With Anipamilmentioning

confidence: 99%

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Szentandrássy

Nagy²,

Hegyi³

et al. 2014

CPD

View full text Add to dashboard Cite

Cardiac arrhythmias are a major cause of morbidity and mortality in the industrialized world. Among their treatment regimens one can find the calcium channel antagonists (CCAs), the class IV agents. In the cardiovascular system Land T-type calcium channels are found on vascular smooth muscle cells and cardiac myocytes with well defined physiological roles. Inhibition of calcium channels by CCAs has widely been used in clinical practice for several decades. Cardiovascular disorders are one of the many fields of medicine in which CCAs are used for various reasons and conditions. The three main indications of them are hypertension, angina and various cardiac arrhythmias. The most important classes of CCAs are dihydropyridines, phenylalkylamines and benzothiazepines but some newer compounds do not fall into any of these major classes. Dihydropyridines are not used in the antiarrhythmic therapy but are good vasodilators and antianginal agents. In contrast, phenylalkylamines and benzothiazepines exert cardiac actions in vivo and therefore these are one choice of antiarrhythmic drugs. This review focuses on phenylalkylamines, benzothiazepines and on new drugs with potential antiarrhythmic action in the heart as well as the mechanisms how calcium channels antagonism can lead to an antiarrhythmic action.

show abstract

“…Los pacientes que no se encuentran en insuficiencia cardíaca presentan pocas restricciones al tratamiento farmacológico, por lo que se pueden elegir los principios más eficaces o de acción más rápida, como los bloqueadores beta y los antagonistas del calcio no hidropiridínicos, el diltiacem y el verapamilo. Estos fármacos han mostrado su eficacia para el control de la respuesta ventricular, tanto en reposo como durante el ejercicio 45,46 , y cualquiera de ellos puede ser de primera elección. La elección del fármaco se realizará fundamentalmente por sus posibles efectos colaterales en relación con el perfil clínico y las enfermedades concomitantes del paciente 41,[47][48][49][50] .…”

Section: Control De La Respuesta Ventricularunclassified

Documento de consenso sobre el tratamiento de la fibrilación auricular en los servicios de urgencias hospitalarios

et al. 2003

View full text Add to dashboard Cite

Este documento se envió asimismo a la revista oficial de la SEMES, Emergencias, para su publicación. Consensus Document for the Management of Patients With Atrial Fibrillation in Hospital Emergency Departments Atrial fibrillation (AF) is the most prevalent arrhythmia in hospital emergency departments and is a serious disease associated with a twofold increase in morbidity and a high mortality rate. However, the management of AF in this scenario is variable and frequently inadequate. This is probably a consequence of the diverse clinical aspects and therapeutic options to consider in the management of patients with AF. Therefore, implementation of specific, coordinated management strategies by the different care providers involved is needed to improve the quality of care and optimize the use of human and material resources. This document presents the guidelines recommended by the Spanish Society of Cardiology (SEC) and the Spanish Society of Emergency Medicine (SEMES) for the management of AF in hospital emergency departments. These guidelines are based on published scientific evidence and are applicable to most emergency departments in Spain. Specific management strategies are proposed for the conversion and maintenance of sinus rhythm, heart rate control during AF, prophylaxis for thrombi and emboli, and hospital admission and discharge protocols.

show abstract

Diltiazem and Exercise Performance in Patients with Chronic Atrial Fibrillation

Cited by 51 publications

References 37 publications

The peri‐operative management of atrial fibrillation

The peri‐operative management of atrial fibrillation

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Documento de consenso sobre el tratamiento de la fibrilación auricular en los servicios de urgencias hospitalarios

Contact Info

Product

Resources

About